# Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

> **NCT07187479** · NA · RECRUITING · sponsor: **Well Cell Global** · enrollment: 120 (estimated)

## Conditions studied

- Chronic Kidney Disease (Stages 4 and 5)
- Kidney Disease
- Type 2 Diabetes

## Interventions

- **OTHER:** Physiologic Insulin Resensitization (PIR)

## Key facts

- **NCT ID:** NCT07187479
- **Lead sponsor:** Well Cell Global
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-14
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07187479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07187479, "Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT07187479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*